OnKure (OKUR) CEO Nicholas Saccomano Receives Repriced Options and Awards

What Happened

• Nicholas A. Saccomano, President & CEO and a director of OnKure Therapeutics (OKUR), was the recipient of a one-time option repricing and an award on August 7, 2026. The filing shows a 150,000-share derivative award recorded at $0.00 and the surrender/cancellation of existing option interests (totaling 571,423 option shares) and the simultaneous grant of replacement derivative awards for the same amounts. Under the Option Repricing, the exercise price of the repriced options was amended to $4.14 per share (the closing price on the Effective Date); many of the original options had exercise prices of $10.00 or higher.

Key Details

• Transaction date: August 7, 2026 (Filed Aug 11, 2026; filing appears timely).
• Reported derivative activity: acquired 150,000 shares @ $0.00 and acquired replacement options totaling 571,423 shares after surrendering/cancelling the same 571,423-option positions; combined derivative share interests affected = 721,423 shares.
• New exercise price for repriced options: $4.14 per share (reduced from prior ≥ $10.00).
• Retention/early-exercise rule: if a holder exercises a repriced option before the end of the Retention Period (through Feb 7, 2028 or a Change in Control), they must pay a premium exercise price equal to the option's original exercise price (i.e., early exercise requires the original higher price).
• Vesting: some reported awards/options are fully vested (F2); others vest monthly under 36- or 48-month schedules with various start dates (see F1, F5, F6).
• Shares owned after the transactions: not specified in the summary data provided.

Context

• These are derivative transactions (option/award repricing and grants), not open-market purchases or sales. The filing reflects the company’s one-time repricing program that replaced higher-strike options with options set to the closing market price on Aug 7, 2026. This does not represent an immediate cash purchase or sale by the insider; instead it changes the exercise economics of existing option awards. Retail investors should view this as a compensation-related amendment rather than a direct insider buy/sell signal.